Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02661503 | HD21 for Advanced Stages | unknown | Phase 3 | 1,500 | University of CologneOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT05518318 | GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL) | unknown | Phase 3 | 60 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 0 | Aug 26, 2022 | clinicaltrials |
| Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma |
| unknown |
| Phase 3 |
| 56 |
| Jiangsu HengRui Medicine Co., Ltd.INDUSTRY |
| 1 |
| Feb 8, 2021 |
| clinicaltrials |
| NCT00736320 | HD16 for Early Stage Hodgkin Lymphoma(HD16) | unknown | Phase 3 | 1,150 | University of CologneOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT04510610 | Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | unknown | Phase 2 / Phase 3 | 100 | Chinese PLA General HospitalOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT02722733 | Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | unknown | Phase 3 | 90 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Mar 30, 2016 | clinicaltrials |
| NCT00816959 | Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma | unknown | Phase 3 | 1,200 | American Scitech InternationalOTHER | 1 | Jul 20, 2011 | clinicaltrials |
Data updated 22 days agoSource updated May 13, 2024source: clinicaltrials